Literature DB >> 21733709

Pulmonary artery banding: still a valuable option in developing countries?

Andre Brooks1, Agneta Geldenhuys, Liesl Zuhlke, Paul Human, Peter Zilla.   

Abstract

OBJECTIVE: We examined whether the socio-economic circumstances of a developing country justify pulmonary artery banding (PAB) for the deferral of perceived high-risk patients requiring biventricular repair.
METHODS: A retrospective cohort analysis was done on 143 consecutive patients with ventricular anatomy suitable for a biventricular repair, who had a pulmonary artery band applied between 1 January 2002 and 31 December 2007 as they were considered too high a risk to undergo corrective surgery. The goal in all patients was to lower their risk of definitive surgery by improving their clinical condition. The minimum follow-up period was 2 years with the closing date for data collection being 31 January 2010. The mean weight and age at PAB was 5.34 ± 2.94 kg and 9.9 ± 17.3 months. The endpoints of the study were mortality, interval hospital readmission, growth pattern post-banding, whether or not definitive correction was achieved, and the current follow-up status of uncorrected patients.
RESULTS: The hospital mortality was 8% (n = 12), the inter-stage mortality 21% (n = 30), and the total mortality 29% (n = 42). Positive growth was not shown in 50% following the banding procedure. The mean number of inter-current hospital admissions was 1.5 ± 2 times per patient. At the termination of data collection, after a mean interval of 24.5 ± 14.3 months, debanding and full correction was achieved in 43% (n = 62). In addition to the 29% (n = 42) that were confirmed to be dead, an additional 28% (n = 39) were not corrected and of these almost half were regarded as lost to follow-up. Thus, of the entire cohort of patients, 57% (n = 81) have not achieved definitive correction at the termination of data collection.
CONCLUSION: A strategy of deferring biventricular repair by the application of a pulmonary artery band is ineffective under Third World conditions largely due to lack of patient compliance. This study shows that the overall mortality in the inter-stage period following PAB is high prior to definitive correction. Less than half of patients will eventually be repaired in a reasonable time frame and patient follow-up is unreliable. We conclude that consideration should be given to early definitive repair even in perceived high-risk cases.

Entities:  

Mesh:

Year:  2011        PMID: 21733709     DOI: 10.1016/j.ejcts.2011.05.053

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Authors:  Gerald Maarman; Sandrine Lecour; Ghazwan Butrous; Friedrich Thienemann; Karen Sliwa
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

2.  Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI).

Authors:  Antonio Augusto Lopes; Robyn J Barst; Sheila Glennis Haworth; Marlene Rabinovitch; Maha Al Dabbagh; Maria Jesus Del Cerro; Dunbar Ivy; Tarek Kashour; Krishna Kumar; S Harikrishnan; Michele D'Alto; Ana Maria Thomaz; Leína Zorzanelli; Vera D Aiello; Ana Olga Mocumbi; Maria Virginia T Santana; Ahmed Nasser Galal; Hanaa Banjar; Omar Tamimi; Alexandra Heath; Patricia C Flores; Gabriel Diaz; Julio Sandoval; Shyam Kothari; Shahin Moledina; Rilvani C Gonçalves; Alessandra C Barreto; Maria Angélica Binotto; Margarida Maia; Fahad Al Habshan; Ian Adatia
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

Review 3.  Congenital Heart Disease in Low- and Lower-Middle-Income Countries: Current Status and New Opportunities.

Authors:  Liesl Zühlke; John Lawrenson; George Comitis; Rik De Decker; Andre Brooks; Barend Fourie; Lenise Swanson; Christopher Hugo-Hamman
Journal:  Curr Cardiol Rep       Date:  2019-11-29       Impact factor: 2.931

Review 4.  Congenital heart disease and rheumatic heart disease in Africa: recent advances and current priorities.

Authors:  Liesl Zühlke; Mariana Mirabel; Eloi Marijon
Journal:  Heart       Date:  2013-05-16       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.